Alport Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Eloxx Pharma, Biogen, River 3 Renal Corp., Traverse

DelveInsight’s “Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast

Some of the key facts of the Alport Syndrome Market Report: 

• The Alport Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In September 2023, Eloxx Pharmaceuticals has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for ELX-02. This submission aims to seek approval for conducting a pivotal trial in the treatment of Alport syndrome, specifically targeting cases with nonsense mutations.
• In October 2023, The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency provided a favorable opinion on Calliditas Therapeutics’ request for orphan drug designation in the European Union for setanaxib intended for the treatment of Alport syndrome.
• The overall number of prevalent cases of Alport syndrome across the 7 Major Markets (7MM) in 2022 was approximately 159,000.
• In the United States in 2022, the total number of prevalent cases of Alport syndrome was close to 67,600.
• Within the European Union Four (EU4) and the United Kingdom, Germany recorded the highest total prevalent cases of Alport syndrome in 2022, while Spain reported the lowest prevalent cases for the same period.
• Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
• Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
• In 2022, there were around 2,200 cases of Alport syndrome in the age group 2-11, nearly 1,900 cases in the age group 12-17, and almost 25,000 cases in the age group 18 and above across the 7 Major Markets (7MM).
• The Alport Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alport Syndrome pipeline products will significantly revolutionize the Alport Syndrome market dynamics.

Get a Free sample for the Alport Syndrome Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/alport-syndrome-market

Alport Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alport Syndrome Epidemiology Segmentation:

The Alport Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Alport Syndrome
• Prevalent Cases of Alport Syndrome by severity
• Gender-specific Prevalence of Alport Syndrome
• Diagnosed Cases of Episodic and Chronic Alport Syndrome

Download the report to understand which factors are driving Alport Syndrome epidemiology trends @ Alport Syndrome Epidemiology Forecast

Alport Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alport Syndrome market or expected to get launched during the study period. The analysis covers Alport Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alport Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alport Syndrome Therapies and Key Companies

• ELX-02: Eloxx Pharmaceuticals, Inc.
• Bardoxolone Methyl: Biogen
• R3R01: River 3 Renal Corp.
• Sparsentan: Travere Therapeutics, Inc.
• Atrasentan: Chinook Therapeutics U.S., Inc.
• Finerenone: Bayer

Discover more about therapies set to grab major Alport Syndrome market share @ Alport Syndrome Treatment Landscape

Alport Syndrome Market Strengths

• With a deeper understanding of the genetic basis of Alport syndrome, personalized treatment strategies can be tailored to an individual’s specific genetic profiles. ELX-02 is expected to garner the first mover advantage in Alport syndrome apart from being the first gene therapy with reduced frequency of administration (8 weeks).
• An increase in research and development has paved the way for discovering novel MoA therapies such as dual NOX inhibitor (setanaxib), semaphorin-3A blocker (BAY3401016), selective endothelin A receptor antagonist (atrasentan) amidst the usage of ACE/ARB inhibitors as standard of care.

Alport Syndrome Market Opportunities

• Genetic advances may open the way for personalized treatment tailored to the particular genetic profiles of individuals with Alport syndrome. Thus, there is a huge opportunity for precision medicine approaches.
• Patient advocacy groups such as the Alport Syndrome Foundation can play a pivotal role in shaping the landscape for Alport syndrome. This foundation directs the majority of its resources to research and research-related activities resulting in groundbreaking knowledge and clinical trials pertaining to Alport syndrome.

Scope of the Alport Syndrome Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
• Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
• Alport Syndrome Therapeutic Assessment: Alport Syndrome current marketed and Alport Syndrome emerging therapies
• Alport Syndrome Market Dynamics: Alport Syndrome market drivers and Alport Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Alport Syndrome Unmet Needs, KOL’s views, Analyst’s views, Alport Syndrome Market Access and Reimbursement 

To know more about Alport Syndrome companies working in the treatment market, visit @ Alport Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Alport Syndrome Market Report Introduction

2. Executive Summary for Alport Syndrome

3. SWOT analysis of Alport Syndrome

4. Alport Syndrome Patient Share (%) Overview at a Glance

5. Alport Syndrome Market Overview at a Glance

6. Alport Syndrome Disease Background and Overview

7. Alport Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Alport Syndrome 

9. Alport Syndrome Current Treatment and Medical Practices

10. Alport Syndrome Unmet Needs

11. Alport Syndrome Emerging Therapies

12. Alport Syndrome Market Outlook

13. Country-Wise Alport Syndrome Market Analysis (2019–2032)

14. Alport Syndrome Market Access and Reimbursement of Therapies

15. Alport Syndrome Market Drivers

16. Alport Syndrome Market Barriers

17.  Alport Syndrome Appendix

18. Alport Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services